Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfotanshinone sodium (sodium tanshinone IIA sulfonate) is a water-soluble derivative of tanshinone IIA, a major active lipophilic component extracted from the root of *Salvia miltiorrhiza* (Danshen), a traditional Chinese medicinal herb. It has been approved in China for the treatment of cardiovascular diseases, including coronary heart disease, angina pectoris, myocardial infarction, and ischemic stroke. It exhibits anti-inflammatory, antioxidant, and anti-apoptotic properties. It acts as a negative allosteric modulator of the purinergic receptor P2X7 and inhibits store-operated calcium entry (SOCE) by downregulating canonical transient receptor potential (TRPC) channels, specifically TRPC1 and TRPC6. It is also being investigated for other indications, such as chronic renal failure (to prevent arteriovenous fistula complications) and pulmonary hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfotanshinone sodium.